Showing 8451-8460 of 10141 results for "".
- Galderma Laboratories Launches qilib Hair Care Linehttps://practicaldermatology.com/news/galderma-laboratories-launches-qilib-hair-care-line/2458659/Galderma Laboratories, L.P., launched qilib Hair Regrowth + Revitalization System and qilib Hair Health Reinforcement Biotin + Multivitamin Supplement. The qilib portfolio features a dual action system to address hair thinning and hair loss. Despite the 80 million men and women in the US who suff
- Khloé Kardashian Kicks Off Kybella Campaign in NYChttps://practicaldermatology.com/news/khlo-kardashian-kicks-off-kybella-campaign-in-nyc/2458669/Khloé Kardashian helped Allergan plc kick off their new Live Chin Up campaign. The campaign is designed to help encourage people to not let the things that bother them get in their way. At the event, Kardashian moderated a panel of experts who discussed submental fullnes
- Cipher Launches Bionect Foamhttps://practicaldermatology.com/news/cipher-launches-bionect-foam/2458678/Cipher Pharmaceuticals’ prescription topical Bionect® is now available in the US in a lightweight foam preparation that holds its shape until application. The company says the for
- Hilary Baldwin, MD, Named Medical Director of ATRChttps://practicaldermatology.com/news/hilary-baldwin-md-named-medical-director-of-atrc/2458710/The newly opened Acne Treatment and Research Center (ATRC) in Morristown, NJ, has tapped Hilary Baldwin, MD, to serve as its medical director. Dr. Baldwin received her BA and MA in biology from Boston Uni
- Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetrikshttps://practicaldermatology.com/news/otsuka-licenses-pre-phase-3-topical-atopic-dermatitis-treatment-to-medimetriks/2458712/Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. have entered into a licensing agreement granting Medimetriks exclusive development, manufacturing and commercialization rights for OPA-15406 in
- Valeant: FDA Accepts BLA for Brodalumabhttps://practicaldermatology.com/news/valeant-fda-accepts-bla-for-brodalumab/2458726/The FDA has accepted for review the Biologics License Application (BLA) submitted by AstraZeneca in partnership with Valeant, for brodalumab injection, 210mg, a monoclonal antibody that targets the IL-17 receptor, in development for patients with moderate-to-severe plaque psoriasis. The FDA has a
- DERMAFLASH® Brings Benefits of Dermaplaning Homehttps://practicaldermatology.com/news/dermaflash-brings-benefits-of-dermaplaning-home/2458738/DERMAFLASH™ is the newest addition to the DIY beauty device market. Designed specifically for women, the noninvasive exfoliation device is based on the principles of dermaplaning. DERMAFLASH uses sonic vibration to sweep away dead skin cells, vellus and even coarser
- New World Market for Prescription Dermatological Drugs Report Releasedhttps://practicaldermatology.com/news/new-world-market-for-prescription-dermatological-drugs-report/2458749/Research and Markets recently added the "World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer,Melasma and Seborrhea Treatments)&qu
- Advancing Age May Affect Psoriasis Patients' Access to Biologicshttps://practicaldermatology.com/news/advancing-age-may-affect-psoriasis-patients-access-to-biologics/2458746/Elderly psoriasis patients may be less likely to receive biologics, according to a new study out of Umeå University in Sweden. Specifically, an age increase of 30 years resulted in an average 65 percent reduction in likelihood of obtaining treatment with biologics in this population
- Psoriasis Treatment Update: Rx Enstilar® Is Herehttps://practicaldermatology.com/news/psoriasis-treatment-update-rx-enstilaris-is-here/2458747/Enstilar®, the recently approved plaque psoriasis foam, is now available in pharmacies by prescription. Manufactured by LEO Pharma, Inc., Enstilar